Lilly showcases Jaypirca combination data in CLL at EHA26, debuting results from Ajax acquisition

Eli Lilly highlighted new blood‑cancer data at the European Hematology Association meeting in Stockholm. The company presented early clinical results for its Jaypirca therapy combined with the standard of care in chronic lymphocytic leukemia.

The data represent the first public readout from Lilly's recent acquisition of Ajax, marking a milestone for the integrated development program. While detailed efficacy outcomes were not disclosed, the presentation signals progress in expanding Lilly's portfolio in hematologic malignancies.

Analysts will watch for further details on the trial design and patient responses as the data are fully released, which could inform future regulatory discussions and potential market positioning for the combination regimen.